Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Nol + Pantoprazole for NSAID-induced Gastropathy
NCT02788123Phase 4Terminated
- Sponsor
- Astellas Pharma
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bismuth subcitrate in NSAID-induced gastropathy (2 arms), sponsored by Astellas Pharma. Primary endpoint: Proportion of subjects reaching complete healing of NSAID-induced gastropathy at 2 weeks. Started Mar 2017; status: terminated.
02
Drugs
bismuth subcitrate
03
Conditions
NSAID-induced gastropathy
Beyond the preview
Go deeper on NCT02788123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788123.